Abstract:BackgroundEach year, influenza is responsible for hundreds of thousand cases of illness and deaths worldwide. Due to the virus’ fast mutation rate, the World Health Organization (WHO) is constantly on alert to rapidly respond to emerging pandemic strains. Although anti-viral therapies exist, the most proficient way to stop the spread of disease is through vaccination. The majority of influenza vaccines on the market are produced in embryonic hen’s eggs and are composed of purified viral antigens from inactivated whole virus. This manufacturing system, however, is limited in its production capacity. Cell culture produced vaccines have been proposed for their potential to overcome the problems associated with egg-based production. Virus-like particles (VLPs) of influenza virus are promising candidate vaccines under consideration by both academic and industry researchers.MethodsIn this study, VLPs were produced in HEK293 suspension cells using the Bacmam transduction system and Sf9 cells using the baculovirus infection system. The proposed systems were assessed for their ability to produce influenza VLPs composed of Hemagglutinin (HA), Neuraminidase (NA) and Matrix Protein (M1) and compared through the lens of bioprocessing by highlighting baseline production yields and bioactivity. VLPs from both systems were characterized using available influenza quantification techniques, such as single radial immunodiffusion assay (SRID), HA assay, western blot and negative staining transmission electron microscopy (NSTEM) to quantify total particles.ResultsFor the HEK293 production system, VLPs were found to be associated with the cell pellet in addition to those released in the supernatant. Sf9 cells produced 35 times more VLPs than HEK293 cells. Sf9-VLPs had higher total HA activity and were generally more homogeneous in morphology and size. However, Sf9 VLP samples contained 20 times more baculovirus than VLPs, whereas 293 VLPs were produced along with vesicles.ConclusionsThis study highlights key production hurdles that must be overcome in both expression platforms, namely the presence of contaminants and the ensuing quantification challenges, and brings up the question of what truly constitutes an influenza VLP candidate vaccine.

Construction and Characterization of Insect Cell-Derived Influenza VLP: Cell Binding, Fusion, and EGFP Incorporation

Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system.

Production of influenza virus-like particles using recombinant insect cells

Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate

Construction of eukaryotic expression plasmid for receptor binding of influenza virus and their expression

Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF

Production of Neuraminidase Virus Like Particles by Stably Transformed Insect Cells: A Simple Process for NA-Based Influenza Vaccine Development

Incorporation of Conserved Nucleoprotein into Influenza Virus-Like Particles Could Provoke a Broad Protective Immune Response in BALB/c Mice and Chickens

Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).

Self‐Assembled Virus‐like Particle Vaccines via Fluorophilic Interactions Enable Infection Mimicry and Immune Protection

Targeted Metabolic Analysis and MFA of Insect Cells Expressing Influenza HA-VLP

Increased efficacy of influenza virus vaccine candidate through display of recombinant neuraminidase on virus like particles

Genetically Engineered, Biarsenically Labeled Influenza Virus Allows Visualization of Viral Ns1 Protein in Living Cells

Influenza vaccines based on virus-like particles.

Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems

Key Proteins Involving in the Assembly and Release of Influenza A Virus-Like Particles (Vlps)

Construction and Expression of the Eukaryotic Expression Vector for Nucleoprotein Gene of Influenza Virus A

Enhancing NA immunogenicity through novel VLP designs

Preparation and identification of the NDV-HA chimeric virus-like particles

Construction of Eukaryotic Expressing Plasmids Encoding HA and HA 1 of Influenza A Virus and Their Transient Expression in HEK293 Cells

Construction of eukaryotic expressing plasmids for NP of influenza A virus and their transient expression in Hela cells